.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
The COLCOT randomized trial evaluated low-dose colchicine started soon after myocardial infarction. Compared with placebo, colchicine reduced the risk of a composite cardiovascular endpoint, driven particularly by reductions in stroke and urgent hospitalization for angina leading to coronary revascularization. The study added evidence that residual inflammatory risk may be a therapeutic target after acute coronary syndrome. For physicians, the practical value lies less in routine colchicine for every post-MI patient and more in understanding the evolving role of inflammation in secondary prevention. Standard therapies—antiplatelets, statins, beta-blockers when indicated, renin–angiotensin system therapy and lifestyle intervention—remain central. Colchicine also has tolerability and drug-interaction considerations, especially gastrointestinal effects and interactions with strong CYP3A4 or P-glycoprotein inhibitors. The trial therefore opens a useful discussion about how newer anti-inflammatory strategies may complement established risk-factor management in selected patients.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
The COLCOT randomized trial evaluated low-dose colchicine started soon after myocardial infarction. Compared with placebo, colchicine reduced the risk of a composite cardiovascular endpoint, driven particularly by reductions in stroke and urgent hospitalization for angina leading to coronary revascularization. The study added evidence that residual inflammatory risk may be a therapeutic target after acute coronary syndrome. For physicians, the practical value lies less in routine colchicine for every post-MI patient and more in understanding the evolving role of inflammation in secondary prevention. Standard therapies—antiplatelets, statins, beta-blockers when indicated, renin–angiotensin system therapy and lifestyle intervention—remain central. Colchicine also has tolerability and drug-interaction considerations, especially gastrointestinal effects and interactions with strong CYP3A4 or P-glycoprotein inhibitors. The trial therefore opens a useful discussion about how newer anti-inflammatory strategies may complement established risk-factor management in selected patients.
Today
The phase 3 ACACIA-HCM trial reveals that aficamten improves cardiac structure, diastolic relaxation, functional capacity, and symptom burden in symptomatic nonobstructive hypertrophic cardiomyopathy, marking a major milestone in targeted myosin inhibition.
6 days back
A clinical study shows that automated breast ultrasound paired with artificial intelligence accurately classifies BIRADS 3-4 lesions, reaching 95% sensitivity and 79% specificity. This diagnostic advance promises to reduce unnecessary core needle biopsies and refine clinical workflows in breast imaging.
3 weeks back
Researchers have engineered freestanding hierarchical-porous BCZT thin films that resist cracking and enhance ultrasonic energy harvesting in soft tissue. Achieving high piezoelectric output and acoustic matching, this lead-free material offers transformative potential for implantable bioelectronics.
6 days back
A novel pathology-adaptive surface engineering strategy uses functionalized plasma polymer coatings to selectively modulate AGE adsorption, reducing oxidative stress and restoring bone formation in diabetic and aging microenvironments.
3 weeks back
A breakthrough study identifies the Klotho/PKCα/CUX1/SPARC/TGFβ-RII axis as a critical driver of podocyte mitochondrial injury and ferroptosis in diabetic kidney disease, unveiling promising molecular targets to halt renal disease progression.
6 days back
